FOR U.S. RESIDENTS ONLY
|
 |

Topical Penlac® (ciclopirox) is an optimal treatment choice for specific patient populations
- Patients with diabetes*
- Patients on multiple medications
- Elderly† and/or pediatric patients‡ (12 years and older) who may require or prefer localized, non-systemic treatment
- Patients who want or need to avoid systemic treatment
Penlac® brushes on once daily and dries quickly
| * | Patients with insulin-dependent diabetes or diabetic neuropathy were not included in the Penlac® pivotal trials. |
| † | Clinical studies of Penlac® did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. |
| ‡ | Based on the safety profile in adults, Penlac® is considered safe for use in children 12 years and older. No clinical trials have been conducted in the pediatric population. |
|
Penlac®, part of a comprehensive management program, includes regular removal of the unattached, infected nail by a health care professional, especially for patients with diabetes. Clinical data regarding use of systemic antifungals and Penlac® is not available to support concomitant use. Penlac® is well-tolerated: treatment-related side effects were periungual erythema (5%) and nail disorders (2%).
Patients with insulin-dependent diabetes or those with diabetic neuropathy were not included in pivotal clinical trials with Penlac®.